Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b

Affiliations

• ¹ Department of Haematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
• ² State Key Laboratory of Experimental Haematology, National Clinical Research Center for Blood Diseases, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
• ³ PharmaEssentia Corporation, Taipei, Taiwan.
• ⁴ The Second Hospital of Tianjin Medical University, Tianjin, China.
• ⁵ Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China.
• ⁶ Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China.
• ⁷ The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
• ⁸ Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China.
• ⁹ Shenzhen Second People's Hospital, Shenzhen, Guangdong, China.
• ¹⁰ Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
• ¹¹ The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
• ¹² Huashan Hospital of Fudan University, Shanghai, China.
• ¹³ Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.
• ¹⁴ Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
• ¹⁵ PharmaEssentia Biotech (Beijing) Limited, Beijing, China.